STERIS plc (STE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

STERIS plc (STE) Healthcare & Pipeline Overview

STERIS plc, founded in 1985 and based in Dublin, is a global leader in infection prevention and procedural solutions. Operating across healthcare, applied sterilization technologies, life sciences, and dental sectors, STERIS provides critical products and services to hospitals, pharmaceutical manufacturers, and other healthcare providers, ensuring sterile environments and supporting medical procedures.

What Is the Investment Thesis for STE?

STERIS plc presents a notable research candidate due to its strong market position in infection prevention and procedural solutions. With a market capitalization of $20.7B and a P/E ratio of 26.07, the company demonstrates financial stability and growth potential. A key value driver is its diverse revenue streams across healthcare, applied sterilization technologies, life sciences, and dental segments. Growth catalysts include increasing demand for sterilization services, expansion into emerging markets, and continued innovation in infection prevention technologies. The company's 12.1% profit margin and 44.1% gross margin highlight its operational efficiency. However, potential risks include regulatory changes, competition from other medical device companies such as PHG: Koninklijke Philips N.V., and economic downturns affecting healthcare spending.

Based on FMP financials and quantitative analysis

STE Key Highlights

Market Cap of $20.7B reflects strong investor confidence in STERIS plc's market position and future growth prospects.

• P/E ratio of 26.07 indicates a premium valuation, suggesting investors expect continued earnings growth.
• Profit Margin of 12.1% demonstrates efficient operations and effective cost management.
• Gross Margin of 44.1% highlights the company's ability to maintain profitability across its diverse product and service offerings.
• Dividend Yield of 1.15% provides a steady income stream for investors, enhancing the stock's attractiveness.

Who Are STE's Competitors?

STE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are STE's Key Strengths?

Comprehensive product and service offerings.

• Strong market position in infection prevention.
• Global presence with diverse revenue streams.
• Established relationships with key customers.

What Are STE's Weaknesses?

Dependence on healthcare spending.

• Exposure to regulatory changes.
• Potential for product liability claims.
• Competition from larger medical device companies.

What Could Drive STE Stock Higher?

New product launches in infection prevention technologies expected in Q3 2026.

• Expansion of sterilization services in Asia-Pacific region.
• Strategic acquisitions to broaden product portfolio and market reach.

What Are the Key Risks for STE?

Changes in healthcare regulations impacting product approvals and market access.

• Economic downturns reducing healthcare spending.
• Competition from other medical device companies.
• Product liability claims related to medical devices.

What Are the Growth Opportunities for STE?

• Expansion in Emerging Markets: STERIS has a significant opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing demand for advanced medical technologies. By establishing strategic partnerships and tailoring its product offerings to local needs, STERIS can tap into these high-growth markets and drive revenue growth. This expansion could contribute an additional 10-15% to overall revenue within the next five years.
• Increasing Demand for Sterilization Services: The growing complexity of medical devices and the rising incidence of healthcare-associated infections (HAIs) are driving increased demand for sterilization services. STERIS's Applied Sterilization Technologies segment is well-positioned to capitalize on this trend by expanding its network of sterilization facilities and offering innovative sterilization solutions. The global sterilization services market is projected to reach $10 billion by 2028, providing a substantial growth opportunity for STERIS.
• Product Innovation and Development: Continued investment in research and development is crucial for STERIS to maintain its competitive edge and drive long-term growth. By developing innovative infection prevention and procedural solutions, STERIS can address unmet needs in the healthcare market and capture new market share. Focus areas include advanced sterilization technologies, automated endoscope reprocessing systems, and surgical equipment. Successful product launches could contribute an additional 5-8% to annual revenue growth.
• Strategic Acquisitions: STERIS has a history of successful acquisitions that have expanded its product portfolio and geographic reach. Pursuing strategic acquisitions of complementary businesses can further strengthen STERIS's market position and accelerate growth. Potential acquisition targets include companies specializing in infection prevention, surgical equipment, and healthcare services. A well-executed acquisition strategy could add 10-12% to revenue within the next three years.
• Growing Dental Segment: The dental segment presents a significant growth opportunity for STERIS. With an increasing focus on oral hygiene and preventive dental care, the demand for dental instruments, infection control products, and water quality products is expected to rise. STERIS can capitalize on this trend by expanding its dental product offerings and strengthening its distribution network. The global dental market is projected to reach $50 billion by 2027, providing a substantial growth opportunity for STERIS.

What Are STE's Competitive Advantages?

• Strong brand reputation in infection prevention and sterilization.
• Extensive network of sterilization facilities.
• Comprehensive product portfolio across multiple healthcare segments.
• Long-standing relationships with key customers.

What Does STE Do?

STERIS plc, established in 1985 and headquartered in Dublin, Ireland, is a global provider of infection prevention and procedural products and services. The company operates through four key segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers a wide array of products, including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, and surgical equipment such as tables, lights, and connectivity solutions. This segment also provides essential services like capital equipment installation, maintenance, and instrument repair. The Applied Sterilization Technologies segment focuses on contract sterilization and testing services for medical device and pharmaceutical manufacturers, operating through a network of approximately 50 facilities. This segment ensures that medical products meet stringent sterilization standards, crucial for patient safety and regulatory compliance. The Life Sciences segment designs, manufactures, and sells consumable products such as cleaning chemistries, barrier and sterility assurance products, sterilizers, and washer disinfectors. It also offers equipment installation, maintenance, and repair services tailored to the needs of pharmaceutical and research facilities. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suites. This segment supports dental professionals in maintaining a safe and sterile environment for patient care. STERIS serves a diverse customer base, including hospitals, healthcare providers, and pharmaceutical manufacturers worldwide. The company's comprehensive portfolio of products and services positions it as a critical partner in maintaining sterile environments and supporting medical procedures across various healthcare settings.

What Products and Services Does STE Offer?

• Provides cleaning chemistries and sterility assurance products for healthcare facilities.
• Offers automated endoscope reprocessing systems and tracking products.
• Manufactures and sells surgical tables, lights, and connectivity solutions.
• Provides contract sterilization and testing services for medical device and pharmaceutical manufacturers.
• Designs and manufactures consumable products such as cleaning chemistries and sterilizers for life sciences.
• Offers hand and powered dental instruments, infection control products, and personal protective equipment for dental suites.
• Provides equipment installation, maintenance, and repair services for healthcare and life sciences equipment.

How Does STE Make Money?

• Sells infection prevention and sterilization products to hospitals and healthcare providers.
• Provides contract sterilization services to medical device and pharmaceutical manufacturers.
• Offers equipment maintenance and repair services.
• Sells dental instruments and infection control products to dental professionals.

What Industry Does STE Operate In?

STERIS plc operates in the medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and growing demand for advanced healthcare solutions. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. STERIS competes with companies like PHG: Koninklijke Philips N.V. and DGX: Quest Diagnostics Incorporated. STERIS's focus on infection prevention and sterilization positions it favorably within this landscape, as healthcare providers increasingly prioritize patient safety and regulatory compliance.

Who Are STE's Key Customers?

• Hospitals and healthcare providers.
• Medical device manufacturers.
• Pharmaceutical manufacturers.
• Dental professionals.

Company Profile

STERIS plc operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Mentor, US. The company is led by CEO Daniel A. Carestio. STE has traded publicly since 1992.

Return on equity for STERIS plc stands at 11.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. STE trades at a trailing price-to-earnings ratio of 26.07, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.8%, the inverse of the P/E and a quick read on earnings relative to price.

STE Valuation & Market Position

With a $20.7B market cap, STERIS plc sits in the large-cap segment of the market. Analyst price targets span from $269.00 to $275.00, with a consensus of $271.33. At the current price of $212.45, that implies approximately 28% upside potential. Relative to its peer group, STE's quantitative score of 85/100 is above the peer average of 67/100.

Quarterly Financial Performance: STERIS plc

Revenue for STERIS plc came in at $1.49B during Q1 FY2027, a 6.0% contraction versus the preceding quarter. The company recorded net income of $200.1M, with diluted EPS of $2.04. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, STE averaged $2.04 in diluted EPS.

STERIS plc's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.03 places it in the safe zone, indicating low near-term bankruptcy risk.

STERIS plc has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.2% above estimates on average.

Over the past six months, STERIS plc insiders filed 67 SEC Form 4 transactions — 32 sales and 35 purchases. On net that is roughly 204K shares acquired (about $35.0M) — insiders putting money in tends to read as conviction.

STE Financials

STE Latest News

STE Analyst Consensus

STE MoonshotScore

Common Questions About STE (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources